Your browser doesn't support javascript.
loading
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Blommestein, Hedwig M; Armstrong, Nigel; Ryder, Steve; Deshpande, Sohan; Worthy, Gill; Noake, Caro; Riemsma, Rob; Kleijnen, Jos; Severens, Johan L; Al, Maiwenn J.
Affiliation
  • Blommestein HM; Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Room No. J8-23, PO Box 1738, 3000 DR, Rotterdam, The Netherlands. blommestein@bmg.eur.nl.
  • Armstrong N; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Ryder S; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Deshpande S; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Worthy G; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Noake C; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Riemsma R; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Kleijnen J; Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Escrick, York, YO19 6FD, UK.
  • Severens JL; School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.
  • Al MJ; Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Room No. J8-23, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.
Pharmacoeconomics ; 34(1): 23-31, 2016 Jan.
Article in En | MEDLINE | ID: mdl-26314282
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Topics: Fomentar_producao_conhecimento_especifico Health context: 1_ASSA2030 Database: MEDLINE Main subject: Technology Assessment, Biomedical / Thalidomide / Myelodysplastic Syndromes / Cost-Benefit Analysis / Anemia, Macrocytic Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Pharmacoeconomics Year: 2016 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Topics: Fomentar_producao_conhecimento_especifico Health context: 1_ASSA2030 Database: MEDLINE Main subject: Technology Assessment, Biomedical / Thalidomide / Myelodysplastic Syndromes / Cost-Benefit Analysis / Anemia, Macrocytic Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Pharmacoeconomics Year: 2016 Document type: Article